R
2R3
vs
D
DAX Index
Over the past 12 months, 2R3 has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +3% growth.
Stocks Performance
2R3 vs DAX Index
Performance Gap
2R3 vs DAX Index
Performance By Year
2R3 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Reata Pharmaceuticals Inc
Glance View
Reata Pharmaceuticals Inc., based in Plano, Texas, has crafted its narrative around the relentless pursuit of innovative therapies targeting serious and life-threatening diseases. The company's story began with a profound commitment to addressing rare genetic diseases affecting the central nervous system—conditions often overlooked by larger pharmaceutical enterprises due to their complexity and limited patient populations. Reata's strategy revolves around leveraging its expertise in molecular biology to develop unique therapeutic solutions that modulate biochemical pathways. Its lead compounds, such as Omaveloxolone, are designed to combat oxidative stress—an underlying pathophysiological factor in many neurological disorders. The company’s business model finds equilibrium between high-stakes innovation and strategic partnerships. By targeting rare diseases with niche but under-penetrated markets, Reata can potentially command premium pricing for its treatments, often under the auspices of orphan drug status which provides regulatory and market exclusivity advantages. Beyond its own pipeline advancements, Reata also extends its financial reach through strategic alliances with major industry players, enhancing its capital influx and accelerating drug development. The complex tapestry of cutting-edge science, strategic foresight, and the ability to navigate regulatory landscapes paints Reata Pharmaceuticals as not only a beacon of hope for patients but also a dynamic player in the biopharmaceutical sector.
